GlassScriptPhysician profile
Marina T Wolfe
NPI 1659642023
$6,683.84
in general payments reported to CMS, 2019-2025
25 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,501 · 2022: $1,848 · 2023: $1,142 · 2024: $531 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,334.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,568.29 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $897.95 | 2022-2025 | Caplyta |
| Alkermes, INC. | $658.07 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $623.45 | 2021-2025 | |
| Indivior INC. | $437.16 | 2021-2025 | Sublocade, Perseris |
| Neurocrine Biosciences, INC. | $395.32 | 2021-2025 | Ingrezza |
| Gilead Sciences, INC. | $207.39 | 2022-2023 | Veklury |
| Janssen Pharmaceuticals, INC | $181.51 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $178.73 | 2024-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $161.31 | 2021-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $159.64 | 2022-2023 | Quviviq |
| Edwards Lifesciences Corporation | $127.16 | 2021 | |
| Evoke Pharma, INC. | $125.00 | 2023 | Gimoti |
| Braeburn INC. | $121.08 | 2024-2025 | Brixadi |
| Esperion Therapeutics, INC. | $119.20 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $112.17 | 2022 | |
| Avanir Pharmaceuticals, INC. | $111.87 | 2021 | |
| Medtronic, INC. | $101.45 | 2021 | |
| Abbott Laboratories | $94.31 | 2022 | |
| Boston Scientific Corporation | $93.88 | 2025 | Watchman Access System |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $91.95 | 2023 | |
| Axsome Therapeutics, INC. | $56.66 | 2025 | Auvelity |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.72 | 2021 | |
| Allergan, INC. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.